ClinicalTrials.gg
CompletedNCT01216072EPOCUpdated Feb 10, 2014Results posted

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

A Phase 4 interventional study of Fingolimod and Standard MS DMTs in Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 149 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
7th of 34
1,053 · median 167
Started
2010
with 3 others
Phase 4
17 of 34
none open now
Registered
10th of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 7th largest by enrollment, is one of 4 that started in 2010, is one of 17 in phase 4, and was the 10th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.

03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing Forms of Multiple Sclerosis
  • Disease Modifying Therapy
  • fingolimod
  • Patient Reported Outcomes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Relapsing forms of MS
  • Expanded Disability Status Scale (EDSS) 0-5.5
  • Continuous treatment with MS DMT for a minimum of 6 months
  • Fingolimod naive

Exclusion criteria

Exclusion Criteria:

  • Immune system diseases other than MS
  • Active macular edema
  • History of selected prior infections and criteria for immunizations
  • History of selected immune system treatments and/or medications
  • Selected cardiovascular, pulmonary, or hepatic conditions
  • Selected abnormal laboratory values
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria applied

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,053 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .

    Drug: Fingolimod

  • Active comparator
    Multiple Sclerosis Disease Modifying Treatments (MS DMTs)

    Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.

    Drug: Standard MS DMTs

Interventions

  • 0.5 mg/day oral capsule

    Also known as: GILENYA™

  • Also known as: Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6

    The TSQM was developed and validated as a general measure for treatment satisfaction. It contains 14 items assessing the following 4 domains: effectiveness (sum of scores for questions 1 - 3), side effects (sum of scores for questions 4 - 8), convenience (sum of scores for questions 9 - 11) and Global Satisfaction (sum of scores for questions 12 - 14). The primary analysis was on Global Satisfaction. Question 12 scored as 1(not at all confident) to 5 (extremely confident); question 13 scored as 1(not at all certain) to 5(extremely certain); and question 14 scored as 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death

    In this analysis, patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.

    Time frame: 9 months (6 month core + 3 month Extension)

  2. Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6

    The PRIMUS activity measure is a 15-item assessment of patient-reported ADL. The PRIMUS-Activities total score was calculated by summing the 15 item scores after recoding the responses from 1 - 3 to 0 - 2. Totals scores range from 0 to 30 with higher scores indicating greater activity limitation. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.

    Time frame: Baseline, Month 6

  3. Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) is a 9-item assessment scale measuring fatigue and its effects, using a scale from 1 to 7, with higher scores indicating greater fatigue, or greater negative effects of fatigue on daily living. The FSS 9 item total score was calculated by summing the first 9 item scores and dividing by the number of non-missing items. If no more than 20% of the items were missing, the total score was the product of the mean response of the non missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.

    Time frame: Baseline, Month 3, Month 6

  4. Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4

    The effectiveness scale was scored as follows: 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

    Time frame: Baseline, Month 6

  5. Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4

    The Side Effects subscale was scored as follows: question 4 scored as 0(no) or 1(yes); question 5 scored as 1(extremely bothersome) to 5(not at all bothersome); and questions 6 - 8 scored as 1(a great deal) to 5(not at all). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

    Time frame: Baseline, Month 6

  6. Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4

    The convenience subscale was scored as follows: questions 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and question 11 scored as 1(extremely inconvenient) to 7 (extremely convenient). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

    Time frame: Baseline, Month 6

  7. Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2)

    The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

    Time frame: Baseline, Month 6

  8. Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II)

    The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory. Each item is scored from 0 to 3. The questions in the BDI-II refer to how the patient has been feeling over the past two weeks specifically. The BDI-II total score was calculated by summing the 21 item scores. Final scores ranged from 0 to 63 where higher scores indicated more severe depression. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change indicates improvement.

    Time frame: Baseline, Month 3, Month 6

  9. Physician-reported Clinical Global Impression of Improvement (CGI-I)

    The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. The assessments were completed at Month 3 and Month 6. A lower score indicates improvement.

    Time frame: Month 3, Month 6

07

Results

Posted Dec 5, 2013

Participant flow

Open-Label Core Period ( 6 Months)
Participant flow — Open-Label Core Period ( 6 Months)
MilestoneFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Started790263
Full analysis set789263
Safety set783245
Completed714229
Not completed7634
Withdrew: Adverse event404
Withdrew: Abnormal laboratory value(s)20
Withdrew: Abnormal test procedure result(s)30
Withdrew: Lack of efficacy34
Withdrew: Withdrawal by subject1222
Withdrew: Lost to follow-up50
Withdrew: Protocol deviation114
Open-Label Extension Period (3 Months)
Participant flow — Open-Label Extension Period (3 Months)
MilestoneFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Started0195
Safety set0193
Completed0181
Not completed014
Withdrew: Adverse event010
Withdrew: Abnormal test procedure results01
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryChange From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6

The TSQM was developed and validated as a general measure for treatment satisfaction. It contains 14 items assessing the following 4 domains: effectiveness (sum of scores for questions 1 - 3), side effects (sum of scores for questions 4 - 8), convenience (sum of scores for questions 9 - 11) and Global Satisfaction (sum of scores for questions 12 - 14). The primary analysis was on Global Satisfaction. Question 12 scored as 1(not at all confident) to 5 (extremely confident); question 13 scored as 1(not at all certain) to 5(extremely certain); and question 14 scored as 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 622.5 ± 27.13.5 ± 20.57
SecondaryNumber of Patients Who Experienced Adverse Events, Serious Adverse Events and Death

In this analysis, patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.

Time frame:
9 months (6 month core + 3 month Extension)
Reported as:
Number · Participants
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
ParticipantsFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)Extension Fingolimod Period
Adverse Events (serious and non-serious)617152123
Serious Adverse Events3157
Death000
SecondaryChange From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6

The PRIMUS activity measure is a 15-item assessment of patient-reported ADL. The PRIMUS-Activities total score was calculated by summing the 15 item scores after recoding the responses from 1 - 3 to 0 - 2. Totals scores range from 0 to 30 with higher scores indicating greater activity limitation. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6-0.6 ± 4.51-0.2 ± 4.97
SecondaryChange From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS)

The Fatigue Severity Scale (FSS) is a 9-item assessment scale measuring fatigue and its effects, using a scale from 1 to 7, with higher scores indicating greater fatigue, or greater negative effects of fatigue on daily living. The FSS 9 item total score was calculated by summing the first 9 item scores and dividing by the number of non-missing items. If no more than 20% of the items were missing, the total score was the product of the mean response of the non missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS)
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change from Baseline to Month 3 (n=710,232)-0.3 ± 1.240.0 ± 1.14
Change from Baseline to Month 6 (n=687,218)-0.4 ± 1.240.0 ± 1.13
SecondaryChange From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4

The effectiveness scale was scored as follows: 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.415.5 ± 27.532.8 ± 19.05
SecondaryChange From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4

The Side Effects subscale was scored as follows: question 4 scored as 0(no) or 1(yes); question 5 scored as 1(extremely bothersome) to 5(not at all bothersome); and questions 6 - 8 scored as 1(a great deal) to 5(not at all). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.422.9 ± 29.893.5 ± 23.18
SecondaryChange From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4

The convenience subscale was scored as follows: questions 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and question 11 scored as 1(extremely inconvenient) to 7 (extremely convenient). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.441.8 ± 22.851.5 ± 18.33
SecondaryChange From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2)

The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2)
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Physical Function (n=745,226)1.5 ± 7.960.4 ± 7.03
Role Limitations d/t Physical Health (n=742,226)2.8 ± 9.651.2 ± 8.51
Bodily Pain (n=742,226)2.0 ± 9.7-0.3 ± 8.38
General Health Perceptions (n=737,224)0.8 ± 8.29-0.3 ± 7.24
Vitality (n=745,227)2.8 ± 8.880.6 ± 7.73
Social Functioning (n=747,227)2.6 ± 10.310.8 ± 10.61
Role Limitation d/t Emotional Problems (n=745,226)1.6 ± 12.48-0.6 ± 11.51
General Mental Health (n=745,227)2.2 ± 9.620.3 ± 9.37
Physical Component Summary Scale (n=724,222)1.7 ± 7.410.3 ± 6.48
Mental Component Summary Scale (n=724,222)2.3 ± 10.030.2 ± 9.62
SecondaryChange From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II)

The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory. Each item is scored from 0 to 3. The questions in the BDI-II refer to how the patient has been feeling over the past two weeks specifically. The BDI-II total score was calculated by summing the 21 item scores. Final scores ranged from 0 to 63 where higher scores indicated more severe depression. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change indicates improvement.

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II)
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Change from Baseline to Month 3 (n=748,236)-3.2 ± 7.17-0.8 ± 6.57
Change from Baseline to Month 6 (n=709,223)-3.4 ± 7.64-0.6 ± 6.76
SecondaryPhysician-reported Clinical Global Impression of Improvement (CGI-I)

The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. The assessments were completed at Month 3 and Month 6. A lower score indicates improvement.

Time frame:
Month 3, Month 6
Reported as:
Mean · units on a scale
Physician-reported Clinical Global Impression of Improvement (CGI-I)
units on a scaleFingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)
Month 3 (n=758,242)3.4 ± 1.023.9 ± 0.72
Month 6 (n=727,228)3.2 ± 1.113.9 ± 0.62

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—31/783 (4%)316/783 (40.4%)
Standard MS DMT—5/245 (2%)51/245 (20.8%)
Fingolimod Extension Phase—7/193 (3.6%)56/193 (29%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventFingolimodStandard MS DMTFingolimod Extension Phase
Multiple sclerosis relapseNervous system disorders5/7832/2450/193
DiarrhoeaGastrointestinal disorders0/7830/2451/193
Gastric ileusGastrointestinal disorders0/7830/2451/193
NauseaGastrointestinal disorders0/7830/2451/193
Small intestinal obstructionGastrointestinal disorders0/7830/2451/193
Chest painGeneral disorders1/7830/2451/193
ChillsGeneral disorders0/7830/2451/193
PainGeneral disorders0/7830/2451/193
PyrexiaGeneral disorders0/7830/2451/193
GastroenteritisInfections and infestations0/7830/2451/193
Most frequent other events
Most frequent other events
EventFingolimodStandard MS DMTFingolimod Extension Phase
HeadacheNervous system disorders97/7838/24519/193
FatigueGeneral disorders90/78314/24510/193
Upper respiratory tract infectionInfections and infestations51/7838/2459/193
DizzinessNervous system disorders50/7837/2457/193
NauseaGastrointestinal disorders48/7835/24511/193
NasopharyngitisInfections and infestations43/78313/2457/193
HypertensionVascular disorders43/7834/2456/193
DiarrhoeaGastrointestinal disorders41/7834/2453/193

Baseline characteristics

Age, Continuous
Age, Continuous(years)FingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)Total
Mean46 ± 9.8245.1 ± 9.8245.8 ± 9.82
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodMultiple Sclerosis Disease Modifying Treatments (MS DMTs)Total
Female601208809
Male18955244
08

Study locations

149 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35209, United States
  • Novartis Investigative Site
    Cullman, Alabama 35058, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85004, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85006, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85013, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85032, United States
  • Novartis Investigative Site
    Tucson, Arizona 85741, United States
  • Novartis Investigative Site
    Anaheim, California 92801, United States
  • Novartis Investigative Site
    Berkeley, California 94705, United States
  • Novartis Investigative Site
    Fresno, California 93710, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    La Habra, California 90631, United States
  • Novartis Investigative Site
    Loma Linda, California 92354, United States
  • Novartis Investigative Site
    Newport Beach, California 92660, United States
  • Novartis Investigative Site
    Oceanside, California 92056, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Walnut Creek, California 94598, United States
  • Novartis Investigative Site
    Boulder, Colorado 80304, United States
  • Novartis Investigative Site
    Colorado Springs, Colorado 80920, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80528, United States
  • Novartis Investigative Site
    Fairfield, Connecticut 06824, United States
  • Novartis Investigative Site
    New London, Connecticut 06320, United States
  • Novartis Investigative Site
    Stratford, Connecticut 06615, United States
  • Novartis Investigative Site
    Dover, Delaware 19901, United States
  • Novartis Investigative Site
    Newark, Delaware 19713, United States
  • Novartis Investigative Site
    Atlantis, Florida 33462-6608, United States
  • Novartis Investigative Site
    Bradenton, Florida 32405, United States
  • Novartis Investigative Site
    Doral, Florida 33166, United States
  • Novartis Investigative Site
    Fort Lauderdale, Florida 33308, United States
  • Novartis Investigative Site
    Hollywood, Florida 33021, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32209, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32216, United States
  • Novartis Investigative Site
    Lighthouse Point, Florida 33064, United States
  • Novartis Investigative Site
    Maitland, Florida 32751, United States
  • Novartis Investigative Site
    Miami, Florida 33015, United States
  • Novartis Investigative Site
    Miami, Florida 33133, United States
  • Novartis Investigative Site
    Pompano Beach, Florida 33060, United States
  • Novartis Investigative Site
    Ponte Vedra Beach, Florida 32082-4627, United States
  • Novartis Investigative Site
    Port Orange, Florida 32127, United States
  • Novartis Investigative Site
    Sarasota, Florida 34243, United States
  • Novartis Investigative Site
    St. Petersburg, Florida 33713, United States
  • Novartis Investigative Site
    Sunrise, Florida 33351, United States
  • Novartis Investigative Site
    Tallahassee, Florida 32308, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Tampa, Florida 33612, United States
  • Novartis Investigative Site
    Vero Beach, Florida 32960, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33407, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30302, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30309, United States
  • Novartis Investigative Site
    Columbus, Georgia 31901, United States
  • Novartis Investigative Site
    Decatur, Georgia 30083, United States
  • Novartis Investigative Site
    Idaho Falls, Idaho 83402, United States
  • Novartis Investigative Site
    Elk Grove Village, Illinois 60007, United States
  • Novartis Investigative Site
    Evanston, Illinois 60201, United States
  • Novartis Investigative Site
    Flossmoor, Illinois 60422, United States
  • Novartis Investigative Site
    Northbrook, Illinois 60062, United States
  • Novartis Investigative Site
    Anderson, Indiana 46011, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46202-5111, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    Merrillville, Indiana 46410, United States
  • Novartis Investigative Site
    Valparaiso, Indiana 46383, United States
  • Novartis Investigative Site
    Des Moines, Iowa 50314-2611, United States
  • Novartis Investigative Site
    Lenexa, Kansas 66214, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Novartis Investigative Site
    Destrehan, Louisiana 70047, United States
  • Novartis Investigative Site
    Hammond, Louisiana 70403, United States
  • Novartis Investigative Site
    Metairie, Louisiana 70001, United States
  • Novartis Investigative Site
    Shreveport, Louisiana 71101, United States
  • Novartis Investigative Site
    Shreveport, Louisiana 71130, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Bethesda, Maryland 20814, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02135, United States
  • Novartis Investigative Site
    Springfield, Massachusetts 01104, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01608, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01665, United States
  • Novartis Investigative Site
    Detroit, Michigan 48201, United States
  • Novartis Investigative Site
    Grand Rapids, Michigan 49503, United States
  • Novartis Investigative Site
    Kalamazoo, Michigan 49007, United States
  • Novartis Investigative Site
    Southfield, Michigan 48034, United States
  • Novartis Investigative Site
    Bolivar, Missouri 65613, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64111, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64132, United States
  • Novartis Investigative Site
    Nixa, Missouri 65714-7807, United States
  • Novartis Investigative Site
    North Kansas City, Missouri 64116, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63104, United States
  • Novartis Investigative Site
    Billings, Montana 59102, United States
  • Novartis Investigative Site
    Freehold, New Jersey 07728, United States
  • Novartis Investigative Site
    Somerset, New Jersey 08873, United States
  • Novartis Investigative Site
    Teaneck, New Jersey 07666, United States
  • Novartis Investigative Site
    Toms River, New Jersey 08755, United States
  • Novartis Investigative Site
    Amherst, New York 14226, United States
  • Novartis Investigative Site
    Latham, New York 12110, United States
  • Novartis Investigative Site
    New York, New York 10023, United States
  • Novartis Investigative Site
    Patchogue, New York 11772, United States
  • Novartis Investigative Site
    Plainview, New York 11803, United States
  • Novartis Investigative Site
    Asheville, North Carolina 28806, United States
  • Novartis Investigative Site
    Burlington, North Carolina 27215, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28204, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28207, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27401, United States

Showing the first 100 of 149 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3. PubMed 26265274 ↗
  • Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, Hunter SF, Huffman C, Kim E, Pestreich L, McCague K, Barbato L; EPOC study investigators. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014 Sep;3(5):607-19. doi: 10.1016/j.msard.2014.06.005. Epub 2014 Jul 4. PubMed 26265273 ↗
  • Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014 Nov 26;14:220. doi: 10.1186/s12883-014-0220-1. PubMed 25424122 ↗
  • Cascione M, Wynn D, Barbato LM, Pestreich L, Schofield L, McCague K. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. J Med Econ. 2013 Jul;16(7):859-65. doi: 10.3111/13696998.2013.802239. Epub 2013 May 20. PubMed 23647445 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2010
First posted
Oct 7, 2010
Start
Aug 2010
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Dec 5, 2013
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01216072
Responsible party
Sponsor
First posted
Oct 7, 2010
Start date
Aug 2010
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Dec 5, 2013
Last update
Feb 10, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion